790 A Phase II Study (TACTI-002) of Eftilagimod Alpha (a Soluble LAG-3 Protein) with Pembrolizumab in PD-L1 Unselected Patients with Metastatic Non-Small Cell Lung(nsclc) or Head and Neck Carcinoma(hnscc)
JOURNAL FOR IMMUNOTHERAPY OF CANCER（2020）
Key words
FDG-PET/CT Imaging
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined